Use of Wackers sythesis pathway is expected to cut manufacturing costs.
RFS Pharma obtained the rights to use Wacker Chemie’s synthesis pathway for the manufacture of its lead anti-HIV drug Amdoxovir® (DAPD). The compound is currently in Phase II studies.
Wacker reports that its production process should lower costs by creating a more efficient and scalable synthesis for Amdoxovir. “The new process utilizes the 2,6-diamino purine route instead of the 6-chloropurine route used previously,” explains Raymond Schinazi, Ph.D., founder and chairman of RFS Pharma. “There are a number of patents covered under this agreement and the expiration date of the last patent is 2022, assuming we don’t get any patent extensions.”